Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Candel Therapeutics ( (CADL) ) has issued an announcement.
Candel Therapeutics announced positive topline results from its phase 3 clinical trial evaluating CAN-2409 viral immunotherapy for intermediate-to-high-risk localized prostate cancer, which met its primary endpoint by demonstrating a statistically significant improvement in disease-free survival. However, the phase 2b trial for low-to-intermediate risk prostate cancer did not meet its primary endpoint, though there was a numerical improvement in outcomes. The company plans to discuss regulatory pathways with the FDA to seek approval for CAN-2409 and intends to further present these findings at upcoming medical conferences.
More about Candel Therapeutics
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. The company is particularly engaged in advancing therapies for localized prostate cancer, a market with significant unmet needs and a potential worth of over $10 billion in the United States alone.
YTD Price Performance: 213.61%
Average Trading Volume: 385,999
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $149.7M
See more insights into CADL stock on TipRanks’ Stock Analysis page.
